SEC Form 4 · accession 0002001011-26-000142
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine Zimmermann
Director
Period of report
Sep 22, 2026
Accepted (ET)
Sep 24, 2026 · 5:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 22, 2026 | F | 115 | $298.50 | D | 3,782 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.